Clinical vAliDation of ARTificial Intelligence in POlyp Detection (CAD-ARTIPOD)

November 29, 2022 updated by: Universitaire Ziekenhuizen KU Leuven
This study is an open label, unblinded, non-randomized interventional study, comparing the investigational artificial intelligence tool with the current "gold standard": Data acquisition will be obtained during one scheduled colonoscopic procedure by a trained endoscopist. During insertion, no action will be taken, colonoscopy is performed following the standard of care. Once withdrawal is started, a second observer (not a trained endoscopist but person trained in polyp recognition) will start the bedside Artificial intelligence (AI) tool, connected to the endoscope's tower, for detection. This second observer is trained in assessing endoscopic images to define the AI tool's outcome. Due to the second observer watching the separate AI screen, the endoscopist is blinded of the AI outcome. When a detection is made by the AI system that is not recognized by the endoscopist, the endoscopist will be asked to relocate that same detection and to reassess the lesion and the possible need of therapeutic action. All detections are separately counted and categorized by the second observer. All polyp detections will be removed following standard of care for histological assessment. The entire colonoscopic procedure is recorded via a separate linked video-recorder.

Study Overview

Status

Completed

Conditions

Detailed Description

This is an investigator-initiated non-randomized prospective interventional trial to validate the performance of a novel state-of-the-art computer-aided detection (CADe) tool for colorectal polyp detection implemented as second observer during routine diagnostic colonoscopy and to evaluate its feasibility in daily endoscopy. Consecutive patients referred for a screening, surveillance or diagnostic colonoscopy will be included.

Patients will undergo a standard colonoscopy performed by a trained endoscopist. A second observer, who is not a trained endoscopist, will follow the procedure on a bedside AI-tool to count the number of detections made by the AI system and categorize the results into positive or negative results as follows (1) true positive, (2) false negative or (3) false positive. In case of a detection of the AI-system that was not seen by the endoscopist or unclear to the second observer, the second observer will ask to re-evaluate the indicated region to determine whether after second look the endoscopist has to take extra action. The entire procedure will be recorded.

There are no additional risks specific to the use of the AI tool to be taken into account. General risk of colonoscopy (i.e.: perforation, bleeding or post-polypectomy syndrome) could occur with the same frequency as that of a colonoscopy without the use of this AI tool.

All patients will receive a standard of care protocol during their colonoscopy. The AI system can only have a beneficial outcome for the patient, a better polyp detection, as it has shown to be non-inferior in terms of accuracy when compared to high detecting endoscopist in our pilot trial

Study Type

Interventional

Enrollment (Actual)

856

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Vlaams-Brabant
      • Leuven, Vlaams-Brabant, Belgium, 3000
        • University Hospitals Leuven

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age ≥40 years
  • Referral for screening, surveillance or diagnostic colonoscopy
  • Able to give informed consent by the patient or by a legal representative

Exclusion criteria for study inclusion

  • <40 years old
  • Referral for a therapeutic colonoscopy
  • Known Lynch syndrome or Familial Adenomatous Polyposis syndrome
  • Any contraindication for colonoscopy or biopsies of the colon
  • Uncontrolled coagulopathy
  • Confirmed diagnosis of inflammatory bowel disease prior to the scheduled colonoscopy
  • Short bowel or ileostomy
  • Pregnancy

Exclusion criteria for study analysis

  • Colonic inflammation of > 30cm during colonoscopy
  • Incomplete colonoscopy for any reason
  • Incomplete recording or technical failure of the artificial intelligence system

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: AI arm
Only one arm in this study. Every patient who is eligible for this study and is included, after informed consent, will receive a standard colonoscopy combined with real-time AI video analysis
Patients will undergo a standard colonoscopy performed by a trained endoscopist. A second observer, who is not a trained endoscopist, will follow the procedure on a bedside AI-tool to count the number of detections made by the AI system and categorize the results into positive or negative results as follows (1) true positive, (2) false negative or (3) false positive.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Total polyp detection during single pass colonoscopy by the artificial intelligence tool in comparison to polyp detection by the endoscopist with endoscopic diagnosis as a gold standard
Time Frame: 1.5 year
1.5 year

Secondary Outcome Measures

Outcome Measure
Time Frame
Total polyp detection during single pass colonoscopy by the artificial intelligence tool in comparison to polyp detection by the endoscopist with histological diagnosis as a gold standard.
Time Frame: 1.5 year
1.5 year
The number of extra detected polyps by artificial intelligence with the endoscopic diagnosis as a gold standard.
Time Frame: 1.5 year
1.5 year
The number of extra detected polyps by artificial intelligence with the histological diagnosis as a gold standard
Time Frame: 1.5 year
1.5 year
The endoscopist's polyp miss rate defined as the additional detection of polyps during colonoscopy
Time Frame: 1.5 year
1.5 year
The false positive rate during clean withdrawal.
Time Frame: 1.5 year
1.5 year

Other Outcome Measures

Outcome Measure
Time Frame
Correlation between the Boston Bowel Preparation Score and the number of false positive detections during colonoscopy
Time Frame: 1.5 year
1.5 year
Correlation between the endoscopist's historical adenoma detection rate and the number of extra detections and false negative detections by the artificial intelligence system.
Time Frame: 1.5 year
1.5 year
Correlation between the polyp size and number of false negatives and additional detections
Time Frame: 1.5 year
1.5 year
Correlation between the Paris classification and the number of false negatives and additional detections.
Time Frame: 1.5 year
1.5 year
Correlation between the total number of polyps per colonoscopy and additional detections.
Time Frame: 1.5 year
1.5 year
Correlation between the experience of the endoscopist and additional detections
Time Frame: 1.5 year
1.5 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 13, 2020

Primary Completion (Actual)

October 28, 2022

Study Completion (Actual)

November 29, 2022

Study Registration Dates

First Submitted

June 18, 2020

First Submitted That Met QC Criteria

June 18, 2020

First Posted (Actual)

June 22, 2020

Study Record Updates

Last Update Posted (Actual)

November 30, 2022

Last Update Submitted That Met QC Criteria

November 29, 2022

Last Verified

November 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

We do not plan to make individual participant data available. We might share a overview of anonymized data with the collaborating institutions.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Polyp of Colon

Clinical Trials on artificial intelligence image processing

3
Subscribe